stockrow
Saturday 7 November 2026
Export COCP’s income statement to Excel — free account
Cocrystal Pharma, Inc.
COCP Healthcare Biotechnology
- Revenue
- −81.1%
- EPS
- −15.0%
- Free cash flow
- −16.8%
Quarter to June 2026, against a year earlier
1.03
0.03
+3.00%
Follow COCP
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 7 | 2 | — | — | — | — | — | 1 | (69.3%) | 110 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | 9.10 | 0.0 pt | ||||||
| EBT | (104) | (7) | (63) | (48) | (10) | (14) | (39) | (18) | (18) | (9) | (10) | (24.0%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | (733.84) | (479.05) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (747.78) | 0.0 pt | ||||||
| Net income | (75) | (1) | (49) | (48) | (10) | (14) | (39) | (18) | (18) | (9) | (10) | (21.1%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 2.47 | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | n/m | |||||
| Earnings | (38.22) | (0.30) | (20.63) | (18.13) | (2.04) | (1.92) | (4.77) | (1.87) | (1.72) | (0.78) | (0.76) | (35.1%) | ||||||
| Cash flow | (7.48) | (3.43) | (3.55) | (0.59) | (2.14) | (1.73) | (2.63) | (1.52) | (1.62) | (0.73) | (0.58) | (22.8%) | ||||||
| Capex | (0.03) | (0.02) | (0.01) | (0.05) | (0.05) | (0.01) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (29.6%) | ||||||
| Free cash flow | (7.51) | (3.45) | (3.57) | (0.64) | (2.19) | (1.73) | (2.64) | (1.53) | (1.62) | (0.73) | (0.58) | (22.9%) | ||||||
| Book value | 52.23 | 52.45 | 28.67 | 9.69 | 11.42 | 10.53 | 4.86 | 2.73 | 0.94 | 0.56 | 0.08 | (39.6%) | ||||||
| Shares, m | 2 | 2 | 2 | 3 | 5 | 7 | 8 | 10 | 10 | 11 | 12 | +21.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 2.41 | 37.27 | — | — | — | — | — | 10.69 | 19.8 | ||||||
| P/B | — | — | — | 0.61 | 1.43 | — | — | — | — | — | 13.60 | 1.0 | ||||||
| EV/Sales | — | — | — | 1.27 | 20.87 | — | — | — | — | — | 9.00 | 11.1 | ||||||
| EV/FCF | — | — | — | (4.88) | (4.17) | — | — | — | — | — | (1.50) | (4.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (15) | (7) | (8) | (2) | (10) | (13) | (21) | (15) | (16) | (8) | (8) | (6.3%) | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (14.9%) | ||||||
| Free cash flow | (15) | (7) | (8) | (2) | (10) | (13) | (22) | (15) | (16) | (8) | (8) | (6.3%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 3 | 1 | 1 | 6 | 33 | 58 | 39 | 26 | 9 | 6 | 1 | +6.2% | |||||
| Net debt | (4) | 0 | (3) | (7) | (33) | (59) | (37) | (26) | (10) | (7) | (2) | +7.7% | ||||||
| Shareholders’ equity | 102 | 105 | 67 | 26 | 53 | 78 | 40 | 26 | 10 | 6 | 1 | (26.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (42.89) | (0.50) | (51.63) | (99.22) | (23.31) | (21.23) | (64.60) | (49.89) | (78.29) | (76.23) | (151.10) | (33.3) pt | |||||
| ROIC | (67.02) | (4.89) | (61.21) | (165.74) | (30.76) | (47.27) | (1,033.57) | 0.00 | 0.00 | 0.00 | 0.00 | +67.0 pt | ||||||
| ROE | (55.48) | (0.59) | (56.94) | (104.04) | (24.67) | (21.81) | (66.32) | (54.54) | (97.50) | (111.40) | (311.68) | (55.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 18 | 10 | 10 | 11 | 13 | 13 | 12 | 12 | 11 | 10 | — | (6.3%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.60 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Cocrystal Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MCRB Seres Therapeutics, Inc. | $20.8M | — (loss-making) | — (loss-making) | +68.95% (above 0%: growing) | n/m | −576.66% (below 0%: shrinking) | 100.00% | (2,723.78%) | Compare |
| ATOS Atossa Therapeutics, Inc. | $20.2M | — (loss-making) | — | −94.28% (below 0%: shrinking) | n/m | −32.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IMMP Prima BioMed Ltd | $19.8M | — | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| BSEM BioStem Technologies, Inc. | $19.4M | — (loss-making) | — (loss-making) | −27.95% (below 0%: shrinking) | n/m | — | 61.28% | (106.35%) | Compare |
| COCP Cocrystal Pharma, Inc. | $19.3M | — (loss-making) | — (loss-making) | −81.05% (below 0%: shrinking) | n/m | −16.75% (below 0%: shrinking) | 100.00% | (3,032.38%) | |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $18.5M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $17.8M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | Compare |
| KTTA Pasithea Therapeutics Corp. | $17.4M | — (loss-making) | — (loss-making) | +1,494.04% (above 0%: growing) | n/m | −21.68% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $19.0M | — | — | +20.50% | — | −329.19% | 30.64% | 0.00% |
Pay and ownership Proxy statement filed 27 May 2026
Ownership
Directors and executive officers, together
39.40%
Phillip Frost
18.50%
Frost Gamma Investments Trust
18.10%
Fred Hassan
14.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement